Radioimmunotherapy for B-cell non-Hodgkin lymphoma

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Radioimmunotherapy is an established and effective treatment in B-cell non-Hodgkin lymphoma (NHL). Currently, two radioimmunoconjugates (RICs) are approved for clinical use in the United States, ibritumomab tiuxetan and tositumomab. Both agents target the CD20 antigen on B-cell lymphoma cells. Although there are differences between these two agents, such as different murine monoclonal antibodies, radioisotopes, and dosimetry techniques,, they share similar toxicity and efficacy profiles. These anti-CD20 RICs are active in patients who are refractory to single-agent rituximab, documenting the added value of the conjugated radioisotope. This review focuses on the current use of these agents in the treatment of previously untreated indolent NHL and relapsed/refractory and transformed NHL.

Original languageEnglish (US)
Pages (from-to)225-231
Number of pages7
JournalClinical Advances in Hematology and Oncology
Volume4
Issue number3
StatePublished - Mar 2006

Fingerprint

Radioimmunotherapy
B-Cell Lymphoma
Immunoconjugates
Non-Hodgkin's Lymphoma
Radioisotopes
CD20 Antigens
Monoclonal Antibodies
Therapeutics

Keywords

  • CD20
  • Ibritumomab tiuxetan
  • NHL
  • Radioimmunotherapy
  • Tositumomab

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Radioimmunotherapy for B-cell non-Hodgkin lymphoma. / Nowakowski, Grzegorz S; Witzig, Thomas Elmer.

In: Clinical Advances in Hematology and Oncology, Vol. 4, No. 3, 03.2006, p. 225-231.

Research output: Contribution to journalArticle

@article{bb771a3b7f6d48d5ab28eae302f1848b,
title = "Radioimmunotherapy for B-cell non-Hodgkin lymphoma",
abstract = "Radioimmunotherapy is an established and effective treatment in B-cell non-Hodgkin lymphoma (NHL). Currently, two radioimmunoconjugates (RICs) are approved for clinical use in the United States, ibritumomab tiuxetan and tositumomab. Both agents target the CD20 antigen on B-cell lymphoma cells. Although there are differences between these two agents, such as different murine monoclonal antibodies, radioisotopes, and dosimetry techniques,, they share similar toxicity and efficacy profiles. These anti-CD20 RICs are active in patients who are refractory to single-agent rituximab, documenting the added value of the conjugated radioisotope. This review focuses on the current use of these agents in the treatment of previously untreated indolent NHL and relapsed/refractory and transformed NHL.",
keywords = "CD20, Ibritumomab tiuxetan, NHL, Radioimmunotherapy, Tositumomab",
author = "Nowakowski, {Grzegorz S} and Witzig, {Thomas Elmer}",
year = "2006",
month = "3",
language = "English (US)",
volume = "4",
pages = "225--231",
journal = "Clinical Advances in Hematology and Oncology",
issn = "1543-0790",
publisher = "Millennium Medical Publishing, Inc.",
number = "3",

}

TY - JOUR

T1 - Radioimmunotherapy for B-cell non-Hodgkin lymphoma

AU - Nowakowski, Grzegorz S

AU - Witzig, Thomas Elmer

PY - 2006/3

Y1 - 2006/3

N2 - Radioimmunotherapy is an established and effective treatment in B-cell non-Hodgkin lymphoma (NHL). Currently, two radioimmunoconjugates (RICs) are approved for clinical use in the United States, ibritumomab tiuxetan and tositumomab. Both agents target the CD20 antigen on B-cell lymphoma cells. Although there are differences between these two agents, such as different murine monoclonal antibodies, radioisotopes, and dosimetry techniques,, they share similar toxicity and efficacy profiles. These anti-CD20 RICs are active in patients who are refractory to single-agent rituximab, documenting the added value of the conjugated radioisotope. This review focuses on the current use of these agents in the treatment of previously untreated indolent NHL and relapsed/refractory and transformed NHL.

AB - Radioimmunotherapy is an established and effective treatment in B-cell non-Hodgkin lymphoma (NHL). Currently, two radioimmunoconjugates (RICs) are approved for clinical use in the United States, ibritumomab tiuxetan and tositumomab. Both agents target the CD20 antigen on B-cell lymphoma cells. Although there are differences between these two agents, such as different murine monoclonal antibodies, radioisotopes, and dosimetry techniques,, they share similar toxicity and efficacy profiles. These anti-CD20 RICs are active in patients who are refractory to single-agent rituximab, documenting the added value of the conjugated radioisotope. This review focuses on the current use of these agents in the treatment of previously untreated indolent NHL and relapsed/refractory and transformed NHL.

KW - CD20

KW - Ibritumomab tiuxetan

KW - NHL

KW - Radioimmunotherapy

KW - Tositumomab

UR - http://www.scopus.com/inward/record.url?scp=33745443343&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745443343&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 225

EP - 231

JO - Clinical Advances in Hematology and Oncology

JF - Clinical Advances in Hematology and Oncology

SN - 1543-0790

IS - 3

ER -